235 related articles for article (PubMed ID: 32062691)
21. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
22. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
23. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
[TBL] [Abstract][Full Text] [Related]
24. PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Coupe N; Corrie P; Hategan M; Larkin J; Gore M; Gupta A; Wise A; Suter S; Ciria C; Love S; Collins L; Middleton MR
Eur J Cancer; 2015 Feb; 51(3):359-66. PubMed ID: 25542057
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
26. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
27. Dabrafenib and Trametinib in Patients With Tumors With
Salama AKS; Li S; Macrae ER; Park JI; Mitchell EP; Zwiebel JA; Chen HX; Gray RJ; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Armstrong DK; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Nov; 38(33):3895-3904. PubMed ID: 32758030
[TBL] [Abstract][Full Text] [Related]
28. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.
Urbonas V; Schadendorf D; Zimmer L; Danson S; Marshall E; Corrie P; Wheater M; Plummer E; Mauch C; Scudder C; Goff M; Love SB; Mohammed SB; Middleton MR
Ann Oncol; 2019 Feb; 30(2):317-324. PubMed ID: 30428063
[TBL] [Abstract][Full Text] [Related]
30. A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Kasuga A; Nakagawa K; Nagashima F; Shimizu T; Naruge D; Nishina S; Kitamura H; Kurata T; Takasu A; Fujisaka Y; Okamoto W; Nishimura Y; Mukaiyama A; Matsushita H; Furuse J
Invest New Drugs; 2015 Oct; 33(5):1058-67. PubMed ID: 26259955
[TBL] [Abstract][Full Text] [Related]
31. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
32. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
33. Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Barbie DA; Spira A; Kelly K; Humeniuk R; Kawashima J; Kong S; Koczywas M
Clin Lung Cancer; 2018 Nov; 19(6):e853-e859. PubMed ID: 30087028
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA; van Geel RMJM; van Brummelen EMJ; Opdam FL; Marchetti S; Steeghs N; Pulleman S; Thijssen B; Rosing H; Monkhorst K; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Cancer Chemother Pharmacol; 2020 May; 85(5):917-930. PubMed ID: 32274564
[TBL] [Abstract][Full Text] [Related]
36. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
37. Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.
Frankel AE; Eskiocak U; Gill JG; Yuan S; Ramesh V; Froehlich TW; Ahn C; Morrison SJ
Neoplasia; 2017 Apr; 19(4):255-260. PubMed ID: 28278423
[TBL] [Abstract][Full Text] [Related]
38. A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
Kurzrock R; Ball DW; Zahurak ML; Nelkin BD; Subbiah V; Ahmed S; O'Connor A; Karunsena E; Parkinson RM; Bishop JA; Ha Y; Sharma R; Gocke CD; Zinner R; Rudek MA; Sherman SI; Azad NS
Clin Cancer Res; 2019 Sep; 25(18):5475-5484. PubMed ID: 31186313
[TBL] [Abstract][Full Text] [Related]
39. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
40. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
